NF Knowledge Series Webinar: Gomekli (Mirdametinib), the Latest FDA-Approved Treatment for NF1

As part of our ongoing monthly NF Knowledge webinar series for families and individuals living with any form of NF, our bonus February topic is Gomekli (mirdametinib).

Hear from Christopher Moertel, MD, lead investigator of the ReNeu clinical trial that secured FDA approval for Gomekli (mirdametinib), SpringWorks’ MEK inhibitor drug. Dr. Moertel will discuss the newest FDA-approved treatment for NF1 plexiform neurofibromas.

This webinar will be recorded.

Registration Link: https://ctf.zoom.us/webinar/register/WN_A1GAyUAGTlq2q7VSD-ymMQ#/registration